GERMS
Thursday, March 6, 2014
Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults | Merck Newsroom Home
Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
‹
›
Home
View web version
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.